Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib) for ...
Although neuroendocrine cancer is an umbrella term for a group of individually rare cancers, it is less rare than official ...
The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...
Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators provide ...
This opening segment establishes the clinical context for a 66 year old man with well differentiated, non functioning, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results